ARTICLE | Company News
FDA to review MDCO's cangrelor
July 2, 2013 12:35 AM UTC
The Medicines Co. (NASDAQ:MDCO) said FDA accepted for review an NDA for IV cangrelor to prevent platelet activation and aggregation in patients undergoing percutaneous coronary intervention (PCI), tho...